Editorial
doi: 10.1016/j.jacc.2009.09.021.
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
- PMID: 20082924
- DOI: 10.1016/j.jacc.2009.09.021
Item in Clipboard
Editorial
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
J Am Coll Cardiol.
.
Free article
No abstract available
Comment on
-
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.J Am Coll Cardiol. 2009 Dec 15;54(25):2353-7. doi: 10.1016/j.jacc.2009.08.035. J Am Coll Cardiol. 2009. PMID: 20082922 Clinical Trial.
-
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62. doi: 10.1016/j.jacc.2009.10.005. J Am Coll Cardiol. 2009. PMID: 20082923 Clinical Trial.
Similar articles
-
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.Circulation. 2006 Mar 21;113(11):1406-14. doi: 10.1161/CIRCULATIONAHA.105.586347. Epub 2006 Mar 13. Circulation. 2006. PMID: 16534008
-
Intensive statin therapy--a sea change in cardiovascular prevention.N Engl J Med. 2004 Apr 8;350(15):1562-4. doi: 10.1056/NEJMe048061. Epub 2004 Mar 8. N Engl J Med. 2004. PMID: 15007111 No abstract available.
-
Intensive lipid lowering with atorvastatin in coronary disease.N Engl J Med. 2005 Jul 7;353(1):93-6; author reply 93-6. doi: 10.1056/NEJM200507073530117. N Engl J Med. 2005. PMID: 16000362 No abstract available.
-
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.Am Heart J. 2006 Feb;151(2):273-81. doi: 10.1016/j.ahj.2005.04.003. Am Heart J. 2006. PMID: 16442888 Review.
-
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].G Ital Cardiol (Rome). 2010 Oct;11(10 Suppl 1):78S-83S. G Ital Cardiol (Rome). 2010. PMID: 21416832 Review. Italian.
Cited by
-
Cardiovascular risk scores do not account for the effect of treatment: a review.Heart. 2011 May;97(9):689-97. doi: 10.1136/hrt.2010.220442. Heart. 2011. PMID: 21474616 Free PMC article. Review.
-
Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial.Diabet Med. 2012 Nov;29(11):e409-16. doi: 10.1111/j.1464-5491.2012.03759.x. Diabet Med. 2012. PMID: 22823477 Free PMC article. Clinical Trial.
-
Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death.Sci Transl Med. 2013 Dec 11;5(215):215re3. doi: 10.1126/scitranslmed.3007328. Sci Transl Med. 2013. PMID: 24337482 Free PMC article.
-
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.JAMA Cardiol. 2019 Dec 1;4(12):1214-1220. doi: 10.1001/jamacardio.2019.3080. JAMA Cardiol. 2019. PMID: 31721979 Free PMC article. Clinical Trial.
-
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.RMD Open. 2024 Apr 12;10(2):e003912. doi: 10.1136/rmdopen-2023-003912. RMD Open. 2024. PMID: 38609322 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
